1. Introduction {#sec1-molecules-23-03186}
===============

Chemotherapy-induced nausea and vomiting (CINV) remain the most common and devastating side-effects associated with cancer treatment. These side effects can lead to the development of serious clinical complications such as electrolyte imbalance, dehydration, weight loss, weakness, fractures and deterioration in behavioral and mental status of the patient. In addition, these side effects can interfere with compliance with treatment as patients may delay or refuse future treatments because of fear of further nausea and vomiting \[[@B1-molecules-23-03186],[@B2-molecules-23-03186]\]. Recently, a number of approaches have been applied to control CINV including medicinal or complementary therapies and the selection and prescription of appropriate approaches will significantly improve the patients' quality of life.

Chemotherapy treatments received in cancer patients are classified into high emetic risk (emesis in nearly all patients), moderate emetic risk (30--90% risk of emesis), low emetic risk and minimal emetic risk emetogenic chemotherapies \[[@B3-molecules-23-03186],[@B4-molecules-23-03186],[@B5-molecules-23-03186]\]. Compared to cisplatin, melphalan, cyclophosphamide and dacarbazine, which have high emetogenic potential, other chemotherapy agents such as anthracyclines, methotrexate, oxaliplatin and carboplatin have moderate emetogenic properties \[[@B3-molecules-23-03186],[@B4-molecules-23-03186],[@B5-molecules-23-03186]\]. Depending on the chemotherapeutic agents and frequency of administration, patients can develop both acute and delayed CINV. According to the most recent guidelines from major medical organizations such as National Comprehensive Cancer Network and American Society of Clinical Oncology, the use of 5-hydroxytryptamine3 (5-HT~3~; serotonin) receptor antagonist, in combination with and neurokinin1 receptor antagonist (aprepitant) and the corticosteroid dexamethasone is recommended in patients receiving moderately emetogenic chemotherapy \[[@B4-molecules-23-03186],[@B5-molecules-23-03186]\]. In the case of highly emetogenic therapy, a four-drug regimen is recommended, including 5-HT~3~ receptor antagonist, neurokinin1 receptor antagonist, dexamethasone and the antipsychotic drug olanzapine \[[@B4-molecules-23-03186],[@B5-molecules-23-03186]\]. To date, the most commonly used 5-HT~3~ receptor antagonists are granisetron and ondansetron (first-generation 5-HT~3~ receptor antagonists) and palonosetron (second-generation 5-HT~3~ receptor antagonists) \[[@B3-molecules-23-03186],[@B5-molecules-23-03186]\]. While granisetron and ondansetron have significant efficacy in the prevention of acute CINV (0--24 h after chemotherapy) in cancer patients receiving moderately and highly emetogenic chemotherapy, palonosetron has a higher potency and efficacy for the management of delayed CINV (after 24--120 h after chemotherapy) \[[@B3-molecules-23-03186],[@B6-molecules-23-03186],[@B7-molecules-23-03186]\]. When combined with 5-HT~3~ receptor antagonist and dexamethasone, the neurokinin1 receptor antagonist aprepitant prevents CINV in patients receiving highly emetogenic chemotherapy \[[@B8-molecules-23-03186]\]. This four-drug regimen is recommended for the control of both acute and delayed CINV \[[@B3-molecules-23-03186],[@B9-molecules-23-03186]\].

The concept that 5-HT~3~ and its receptors are involved in the emetic reflex was revealed in several earlier studies \[[@B10-molecules-23-03186],[@B11-molecules-23-03186]\]. In addition to the classic 5-HT~3~ receptor antagonists, there are many natural compounds derived from plants which inhibit 5-HT~3~ receptors such as the alkaloids cocaine and morphine (for review, \[[@B12-molecules-23-03186]\]), the antimalarial drug quinine \[[@B13-molecules-23-03186]\], cannabinoids, nicotine and terpenes \[[@B12-molecules-23-03186],[@B14-molecules-23-03186],[@B15-molecules-23-03186]\]. In fact, there has been an increasing tendency towards using natural plant products as important therapeutic entities in the treatment of different illnesses. As such, these agents have advantages over synthetic drugs because they have fewer side effects (such as headache and constipation) in patients undergoing CINV \[[@B16-molecules-23-03186]\] and are more cost-effective \[[@B17-molecules-23-03186]\].

Allosteric modulators alter the receptor conformation by binding to a site distinct from the endogenous agonist binding site (orthosteric site) \[[@B18-molecules-23-03186]\]. As a result, the binding and/or functional properties of agonist binding to orthosteric site may be affected \[[@B19-molecules-23-03186]\]. Negative allosteric modulators decrease the efficacy of the endogenous receptor agonist without inducing complete receptor inhibition caused by orthosteric inhibitors and therefore, maintain the native pattern of the receptor activation largely intact \[[@B18-molecules-23-03186],[@B20-molecules-23-03186],[@B21-molecules-23-03186]\]. Compared to homomeric receptors, the heteromeric 5-HT~3~ receptor contains an increased number of potential allosteric sites for drug interaction. As allosteric sites exhibit greater structural diversity than orthosteric sites, they are more likely to allow selective targeting by modulators than orthosteric sites \[[@B18-molecules-23-03186],[@B20-molecules-23-03186],[@B21-molecules-23-03186]\]. In this article, we examine the results of earlier studies on the actions of natural negative allosteric modulators of 5-HT~3~ receptors. Natural negative allosteric modulators of 5-HT~3~ receptors could be used as useful therapeutic agents in the treatment of CINV in the future.

2. 5-hydroxytryptamine3 Receptors {#sec2-molecules-23-03186}
=================================

5-HT~3~ receptors represent one of the seven families of serotonin receptors (5-HT~1--7~). They are members of the Cys-loop ligand-gated ion channel family and therefore, they differ structurally and functionally from the other six classes of G-protein coupled serotonin receptors \[[@B22-molecules-23-03186]\]. The functional 5-HT~3~ receptor is a pentamere of five subunits that surround a water-filled ion channel \[[@B23-molecules-23-03186],[@B24-molecules-23-03186]\]. Each subunit is made of 3 domains: (1) An extracellular domain that forms the ligand-binding site, (2) A transmembrane domain consisting of four membrane-spanning helices (M1--M4) that facilitate ion movement across the membrane, and (3) An intracellular domain formed by the large M3--M4 intracellular loop, which is responsible for receptor modulation, sorting, and trafficking, and contains openings that impact ion conductance \[[@B23-molecules-23-03186],[@B24-molecules-23-03186],[@B25-molecules-23-03186]\]. The endogenous ligand binding site is located in the extracellular domain at the interface of two adjacent subunits, where binding is coordinated by the convergence of six peptide loops \[[@B26-molecules-23-03186]\]. To date, the five different subunits (A--E) of 5-HT~3~ receptor have been cloned but only the A and B subunits have been studied extensively. Moreover, all functional 5-HT~3~ receptors require the presence of at least one A subunit \[[@B25-molecules-23-03186]\].

5-HT~3~ receptors are located in many brain areas and are believed to play important roles in psychiatric disorders such as depression, motility of gastrointestinal system, emesis, neurodevelopment and nociception, \[[@B12-molecules-23-03186],[@B25-molecules-23-03186],[@B27-molecules-23-03186]\]. Like other channels that are permeable to the cations, Na^+^, K^+^, and Ca^2+^ \[[@B28-molecules-23-03186],[@B29-molecules-23-03186],[@B30-molecules-23-03186]\], the 5-HT~3~ receptors mediate fast excitatory depolarizing responses in pre- and post-synaptic neurons in the central and peripheral nervous system \[[@B31-molecules-23-03186]\].

3. 5-hydroxytryptamine3 Receptor-Mediated Nausea and Vomiting {#sec3-molecules-23-03186}
=============================================================

The role of 5-HT~3~ receptors in nausea and vomiting has been well-established \[[@B32-molecules-23-03186],[@B33-molecules-23-03186]\]. The mechanism by which nausea and vomiting are triggered involves 5-HT~3~ receptors both in the central nervous system and the gastrointestinal tract \[[@B34-molecules-23-03186]\]. Vomiting is triggered when afferent impulses from the cerebral cortex, chemoreceptor trigger zone and vagal afferent fibers of the gastrointestinal tract travel to the vomiting center, located in the medulla. Efferent impulses then travel from the vomiting centre to the abdominal muscles, cranial nerves, salivation centre, and respiratory centre, causing vomiting \[[@B35-molecules-23-03186]\]. Large numbers of 5-HT~3~ receptors are expressed by enteric sensory neurons in the mucosal layer and in the nerve cell body of interneurons and motor neurons in the enteric nervous system \[[@B36-molecules-23-03186]\]. It has been suggested that vomiting occurs because of the stimulation of enterochromaffin cells of the intestinal mucosa which results in the release of 5-HT and subsequent stimulation of peripheral 5-HT~3~ receptors of ganglionic and synaptic transmission in the myenteric plexus. This action, along with the local release of 5-HT in the area postrema, located on the dorsal surface of the medulla oblongata, is suggested to trigger the vomiting reflex \[[@B37-molecules-23-03186]\].

Currently, there is a wide range of 5-HT~3~ antagonists available for clinical use. In fact, drugs that selectively antagonize 5-HT~3~ receptors are currently among the most effective antiemetic agents, and therefore are considered the "gold standard" in the treatment of CINV \[[@B25-molecules-23-03186],[@B34-molecules-23-03186],[@B37-molecules-23-03186]\]. However, the wide use of synthetic antiemetic drugs has been accompanied with adverse side effects such as headache, hypotension and extra pyramidal side effects \[[@B17-molecules-23-03186]\]. Furthermore, they are ineffective in up to 30% of CINV cases \[[@B16-molecules-23-03186],[@B38-molecules-23-03186]\], warranting the search for more effective anti-emetics for CINV treatment. In this aspect, plants have drawn significant interest in the field of treatment of CINV as compared to chemical drugs due to having more advantages, fewer side effects in patients undergoing CINV, as well as being more cost-effective \[[@B17-molecules-23-03186]\].

4. Natural Negative Allosteric Modulators of 5-hydroxytryptamine3 Receptors {#sec4-molecules-23-03186}
===========================================================================

As 5-HT~3~ receptor antagonists were found to be effective antiemetic agents against CINV, much interest was drawn towards identifying agents that are capable of affecting/modulating the function of 5-HT~3~ receptors \[[@B11-molecules-23-03186],[@B39-molecules-23-03186]\]. In the below sections, we review the effects of natural negative allosteric modulators of 5-HT~3~ receptors.

4.1. Terpenes {#sec4dot1-molecules-23-03186}
-------------

Menthol is a monocyclic terpene alcohol ([Figure 1](#molecules-23-03186-f001){ref-type="fig"}) and a natural product of the peppermint plant *Mentha × piperita* (Lamiaceae). It is commonly used as part of analgesic, antiseptic, topical antipruritic, and cooling formulations. In addition, it is widely used as a natural product in cosmetics, a flavoring agent, and as an intermediate in the production of other compounds. Menthol-containing medications are currently available for a number of conditions, including respiratory diseases, gastrointestinal disorders, common cold, and musculoskeletal pain \[[@B40-molecules-23-03186],[@B41-molecules-23-03186],[@B42-molecules-23-03186]\].

Several studies have reported the potential modulatory effect of menthol on the 5-HT~3~ receptor \[[@B15-molecules-23-03186],[@B43-molecules-23-03186],[@B44-molecules-23-03186],[@B45-molecules-23-03186]\] ([Table 1](#molecules-23-03186-t001){ref-type="table"}). An earlier study conducted by Heimes et al., 2011 used three in vitro models to investigate the effects of peppermint oil and its active constituent, menthol, on 5-HT~3~ receptors. The models included \[^14^C\] guanidinium influx into N1E-115 cells which express 5-HT~3~ receptors, isotonic contractions of ileum isolated rat and equilibrium competition binding studies using GR65630 (3-(5-methyl-1H-imidazol-4-yl)-1-(1-methyl-1H-indol-3-yl)-1-propanone, a radioactively-labeled 5-HT~3~ receptor antagonist. Both peppermint oil and menthol, inhibited the serotonin-induced flux of \[^14^C\] guanidinium into N1E-115 cells that express 5-HT~3~ receptors in a concentration-dependent manner. Furthermore, both compounds were able to reduce serotonin-induced contraction of the ileum isolated from rat. Interestingly, peppermint oil and menthol did not compete for the binding site on 5-HT~3~ receptor, which suggests that they bind to an allosteric binding site that is distinct from the binding site of serotonin \[[@B44-molecules-23-03186]\].

The effects of menthol on the functional properties of human 5-HT~3A~ receptors expressed in *Xenopus laevis* oocytes have been studied by Ashoor et al. \[[@B43-molecules-23-03186]\]. Menthol, at an IC~50~ value of 163 µM, caused an inhibition of the 5-HT-induced inward current. The menthol effect was concentration-dependent and was G-protein-independent as GTPγS activity was unchanged. Furthermore, pretreatment with G~i~ and G~o~ inhibitor, pertussis toxin, did not alter the inhibitory effect of menthol. Furthermore, menthol actions were not stereo-selective as (+), (−) and racemic menthol inhibited the currents mediated by 5-HT~3~ receptor in the same manner \[[@B43-molecules-23-03186]\]. Supporting the data observed by Heimes et al. \[[@B44-molecules-23-03186]\], menthol did not affect the binding of the orthosteric 5-HT~3~ receptor antagonist, GR65630 the 5-HT binding site. In addition, increasing the concentration of 5-HT did not alter the inhibitory effect of menthol, which indicates that menthol acts as an allosteric modulator of 5-HT~3~ receptor as a non-competitive antagonist. Interestingly, menthol has also been shown as a negative allosteric inhibitor of α~7~ \[[@B46-molecules-23-03186]\] and α~4~β~2~ \[[@B47-molecules-23-03186],[@B48-molecules-23-03186]\] nicotinic acetylcholine receptors. Apart from its effect on 5-HT~3~ and nicotinic acetylcholine receptors, menthol was also found to activate TRPM8 receptors \[[@B49-molecules-23-03186],[@B50-molecules-23-03186]\] and receptors for inhibitory neurotransmitters, including GABA~A~ and Glycine \[[@B51-molecules-23-03186],[@B52-molecules-23-03186],[@B53-molecules-23-03186],[@B54-molecules-23-03186]\] ([Table 2](#molecules-23-03186-t002){ref-type="table"}).

Walstab et al. investigated the actions of the aporphine alkaloid boldine and menthol isomers on human recombinant homomeric 5-HT~3A~ and heteromeric 5-HT~3AB~ receptors expressed in HEK293 cells utilizing luminescence-based Ca^2+^ assay, membrane potential assay and radioligand binding assay. Both compounds inhibited the 5-HT-induced activation of 5-HT~3~ receptors at micromolar concentrations. Boldine was a more potent inhibitor to 5-HT~3A~ compared to 5-HT~3AB~ receptors. Interestingly, menthol inhibited both receptors in a non-competitive and stereo-selective manner. (+)-menthol had less potent inhibitory action compared to the (−)-menthol which was 11-fold potent towards the homomeric 5-HT~3A~ receptor \[[@B15-molecules-23-03186]\].

In a recent study, the actions of a number of terpenes and pungent substances on human 5-HT~3A~ receptors recombinantly expressed in *Xenopus laevis* oocyte were tested \[[@B45-molecules-23-03186]\]. The results of this study have shown that 5-HT~3A~ receptors are inhibited by a variety of terpenes and pungent substances with some of them belonging to the vanilloid class. Within the acyclic monoterpenes tested, citronellol and geraniol, which are known as the main constituents of *Rosa damascena* flower essential oils \[[@B96-molecules-23-03186]\], were the most potent blockers for 5-HT~3A~ receptors. Citronellol decreased the 5-HT~3A~ receptor-mediated currents with an IC~50~ of 64 µM. Geraniol was less potent compared to citronellol with an IC~50~ of 188 µM. (−)-Menthol also decreased the 5-HT~3A~ receptor-mediated currents but with lower potency than citronellol (IC~50~ 489 µM) \[[@B45-molecules-23-03186]\]. As citronellol and geraniol have structures similar to menthol, further studies are warranted to test if these compounds utilize the same binding site as menthol on the 5-HT~3A~ receptors.

The effects of terpenoids on 5-HT~3~ receptors were also recently studied by Jarvis et al. \[[@B97-molecules-23-03186]\]. The terpenoids citral, eucalyptol, and linalool were tested for their effects on the electrophysiological and binding properties of human 5-HT~3~ receptors expressed in Xenopus oocytes and HEK293 cells, respectively \[[@B97-molecules-23-03186]\]. All of the terpenoids inhibited 5-HT~3~ receptors with IC~50~ values in the µM range (citral IC~50~ = 120 µM; eucalyptol IC~50~ = 258 µM; linalool IC~50~ = 141 µM) \[[@B97-molecules-23-03186]\]. The IC~50~ values were also comparable to those for similar terpenoid compounds, such as menthol (163 µM) \[[@B43-molecules-23-03186]\].

In addition, all the tested compounds non-competitively inhibited the maximal 5-HT in a concentration-dependent manner and did not compete with the fluorescently-labelled antagonist granisetron. Homology modeling and ligand docking predicted the binding to a transmembrane cavity at the interface of adjacent subunits. This can be explained by the lipophilic nature of these compounds. In fact, the results are consistent with the slow wash-in and wash-out that is observed as the compounds diffuse into the membranes before reaching their target \[[@B55-molecules-23-03186]\]. Collectively, the effects of terpenoids on 5-HT~3~ receptors can be added to the increasing list of structurally related natural plant compounds that modulate voltage- and ligand-gated ion channels \[[@B15-molecules-23-03186],[@B45-molecules-23-03186],[@B46-molecules-23-03186],[@B51-molecules-23-03186],[@B98-molecules-23-03186],[@B99-molecules-23-03186],[@B100-molecules-23-03186],[@B101-molecules-23-03186]\].

4.2. Ginger Constituents {#sec4dot2-molecules-23-03186}
------------------------

The rhizome of *Zingiber officinale* Roscoe (Zingiberaceae), commonly known as ginger, has been used for centuries in treating pregnancy-induced nausea and vomiting \[[@B102-molecules-23-03186],[@B103-molecules-23-03186]\]. The anti-emetic effect of ginger and its active constituents have been investigated in earlier studies to establish the mechanism for their antiemetic activity \[[@B12-molecules-23-03186],[@B104-molecules-23-03186],[@B105-molecules-23-03186]\]. The best characterized constituents of ginger are the pungent substances gingerols and shogaols \[[@B56-molecules-23-03186],[@B106-molecules-23-03186]\]. In particular, the compounds 6-, 8-, 10-gingerol and 6-shogaol were shown in different in vivo studies to be, at least, partly responsible for the anti-emetic properties of ginger \[[@B107-molecules-23-03186],[@B108-molecules-23-03186]\]. In this regard, Abdel-aziz et al. \[[@B106-molecules-23-03186]\] used three different in vitro models to investigate the effects of ginger extracts on 5-HT~3~ receptors: 1) \[^14^C\] guanidinium influx into N1E-115 cells which express 5-HT~3~ receptors, 2) isotonic contractions of the isolated guinea-pig ileum induced by the highly selective HT~3~ receptor agonist SR57227A ((4-amino)-(6-chloro-2-pyridyl)L-piperidine hydrochloride), and 3) equilibrium competition binding studies using a radioactively labeled 5-HT~3~ receptor antagonist (\[^3^H\]GR65630). All tested ginger extracts caused concentration-dependent inhibition of \[^14^C\] guanidinium influx through 5-HT~3~ receptor channels as well as contractions of the guinea-pig ileum induced by SR57227A. The order of potency for both models was: 6-shogaol ≥ 8-gingerol 10-gingerol ≥ 6-gingerol. These compounds did not displace the 5-HT~3~ antagonist \[^3^H\]GR65630 from the ligand binding site neither on intact N1E-115 cells nor on the purified membranes of HEK-293 cells over-expressing the h5-HT~3~ receptor indicating that they are non-competitive inhibitors of 5-HT~3~ receptors \[[@B106-molecules-23-03186]\]. Similarly, in the guinea pig myenteric plexus preparation (bioassay for contractile 5-HT~3~ receptors), the 5-HT maximal responses were depressed by 10-gingerol and 6-shagoal. 10-gingerol decreased the response to 5-HT from 93% to 65 % at an antagonist concentration of 3 µM and to 48% at an antagonist concentration of 5 µM. 6-Shogaol (3 µM) was less potent compared to 10-gingerol and induced depression to 61% at an antagonist concentration of 3 µM. It is concluded that the efficacy of ginger in reducing nausea and vomiting may be based on the inhibitory effect of gingerols and shogaols at 5-HT~3~ receptors \[[@B56-molecules-23-03186]\].

In support of the above study, Walstab et al. \[[@B109-molecules-23-03186]\] showed that ginger extracts and its pungent constituents inhibited the activation of human 5-HT~3A~ and 5-HT~3AB~ receptors heterologously expressed in HEK293 cells in a concentration-dependent manner \[[@B109-molecules-23-03186]\]. Furthermore, with increasing concentration of pungent compounds, ginger extracts inhibited both receptors, confirming that they are part of ginger's active principle. Inhibition potencies of 6-gingerol and 6-shogaol on both receptors were in the low µM range. The non-competitive inhibition of 5-HT~3A~ and 5-HT~3AB~ receptors by ginger extract was confirmed by \[^3^H\]GR65630 binding, showing that the ginger extract did not displace the radioligand from 5-HT~3A~ and 5-HT~3AB~ receptors.

In addition to the previously mentioned ginger extracts, Jin et al. reported that zingerone is a non-competitive inhibitor of 5-HT~3~ on visceral afferent neurons \[[@B58-molecules-23-03186]\]. Using patch-clamp methods, they showed that zingerone inhibited the 5-HT response in a manner similar to the pungent substances 6-shogaol and 6-gingerol. The order of inhibitory potency for these compounds were 6-shogaol \>6-gingerol \>zingerone. The IC~50~ of 6-shogaol and 6-gingerol were 128 and 39 times lower than zingerone, respectively, indicating that 6-shogaol and 6-gingerol are more effective than zingerone. Unlike the competitive 5-HT~3~ receptor antagonist ondansetron, all tested ginger constituents acted as non-competitive antagonists, suggesting that ginger and its pungent constituents exert antiemetic effects by blocking 5-HT-induced emetic signal transmission in vagal afferent neurons \[[@B58-molecules-23-03186]\]. Interestingly, zingerone is the least pungent component of *Zingiber officinale* and is absent in fresh ginger. However, gingerols is converted to zingerone upon cooking or heating. As a consequence, this process reduces the 5-HT~3A~ blocking activity of ginger \[[@B57-molecules-23-03186]\]. Although all data showed that ginger-derived molecules act allosterically, in silico techniques showed that these compounds can also bind to the orthosteric binding site causing competitive inhibition as well \[[@B110-molecules-23-03186]\]. Ginger extracts were also tested against other ion channels such as L-type Ca^2+^, Na^+^ and K^+^ channels. While gingerol caused a dose-dependent inhibition of L-type Ca^2+^ channels in longitudinal mycocytes of rats, both 6-gingerol and 6-shagaol inhibited the generation of action potential in the sensory neurons of rats by inhibiting Na^+^ and K^+^ channels \[[@B80-molecules-23-03186]\].

4.3. Capsaicin {#sec4dot3-molecules-23-03186}
--------------

Capsaicin, from chili pepper, is another pungent substance that has shown effectiveness in reversing emesis in chemotherapy and operation-induced nausea and vomiting \[[@B111-molecules-23-03186],[@B112-molecules-23-03186]\] and in *Cannabis* hyperemesis syndrome \[[@B113-molecules-23-03186],[@B114-molecules-23-03186]\]. Capsaicin is chemically-related to other vanilloid substances such as gingerols and shogaols. Capsaicin was also found to inhibit 5-HT~3~ receptor expressed in *Xenopus laevis* oocytes \[[@B45-molecules-23-03186]\]. When co-applied with 5-HT (5 µM), capsaicin (100 µM) significantly decreased 5-HT-induced currents up to 52% compared to 83% for 8-gingerol, 62% for 6-gingerol, 42% for 6-shogaol, and 65% for polygodial, the hot substance of dorrigo, mountain pepper or black pepper. The concentration-inhibition curves showed that 8-gingerol, 6-gingerol, capsaicin and polygodial blocked 5HT-induced inward currents in a concentration-dependent manner with IC~50~ values of 40 µM, 46 µM, 98 µM and 71 µM, respectively \[[@B45-molecules-23-03186]\]. Other ion channels were also found to be modulated by capsaicin. In fact, capsaicin was found to modulate both K^+^ and Ca^2+^ channels in Xenopus embryo spinal neurons \[[@B45-molecules-23-03186]\].

4.4. Eugenol and Vanilin {#sec4dot4-molecules-23-03186}
------------------------

In addition to the previously mentioned compounds, other agents such as eugenol and vanillin were also found to modulate the activity of 5-HT~3~ receptors. Both agents showed a non-competitive antagonistic activity on 5-HT~3~ receptors expressed in *Xenopus laevis* oocytes, however, very high concentrations of both compounds were needed to inhibit 5-HT response (IC~50~ 1159 µM for eugenol and IC~50~ 4744 µM for vanillin) making them less effective compared to the other antagonists \[[@B45-molecules-23-03186]\]. Eugenol could also inhibit the actions of different isoforms of T-type Ca^2+^ channels \[[@B83-molecules-23-03186]\] and activate the inhibitory receptor GABA \[[@B85-molecules-23-03186],[@B86-molecules-23-03186]\].

4.5. Thujone {#sec4dot5-molecules-23-03186}
------------

The monoterpene thujone is chemically related to menthol and found in plants such as wormwood, thyme and sage \[[@B19-molecules-23-03186]\]. Similar to menthol, thujone has been shown to non-competitively suppress the function of 5-HT~3~ receptors. Using patch clamp technique, Alpha-thujone was found to cause a significant inhibition of both homomeric and heteromeric 5-HT~3~ receptors expressed in HEK293 cells. However, the effective concentration was typically in the high µM range \[[@B115-molecules-23-03186]\]. Furthermore, other ligand-gated ion channels were reported to be sensitive to thujone, including GABA~A~ receptors and α7-nicotinic receptors. Thujone caused a non-competitive inhibition of both receptors expressed in HEK 293 cells and Xenopus oocytes, respectively \[[@B94-molecules-23-03186]\].

4.6. Cannabidiol {#sec4dot6-molecules-23-03186}
----------------

Previous studies showed that both 5-HT~3~ receptor antagonists and cannabinoids produce antiemetic effects \[[@B32-molecules-23-03186],[@B59-molecules-23-03186]\]. In fact, dronabinol and nabilone which are synthetically produced from Δ^9^-tetrahydrocannabinol, the main psychoactive constituent of *Cannabis sativa*, were approved by the United States FDA for use in CINV refractory to conventional antiemetic therapy \[[@B32-molecules-23-03186],[@B59-molecules-23-03186],[@B116-molecules-23-03186]\]. The limitation of the therapeutic use of THC and its other chemical analogs is the potential development of psychoactive effects through cannabinoid receptors (CB1) present in the central nervous system.

The compound cannabidiol is one of the most abundant cannabinoids of *Cannabis* plant with reported antioxidant, anti-inflammatory, and antiemetic effects. Furthermore, this compound lacks any psychoactive properties due to the low affinity for the cannabinoid receptors, CB1 and CB2 \[[@B117-molecules-23-03186],[@B118-molecules-23-03186],[@B119-molecules-23-03186]\]. Thus, pharmaceutical interest in this compound has increased significantly in recent years \[[@B19-molecules-23-03186],[@B117-molecules-23-03186],[@B119-molecules-23-03186],[@B120-molecules-23-03186]\]. The effect of cannabidiol on the function of 5-HT~3A~ receptors expressed in *Xenopus laevis* oocytes was investigated using two-electrode voltage-clamp techniques. Cannabidiol was capable of reversing 5-HT-evoked currents in a concentration-dependent manner, with an IC~50~ = 0.6 µM \[[@B121-molecules-23-03186]\]. Although the potency of the 5-HT was not altered, its efficacy was significantly decreased by cannabidiol, indicating that cannabidiol did not compete with the 5-HT binding site on the receptor. In agreement with these findings, radioligand binding studies indicated that displacement of \[^3^H\]GR65630 by 5-HT was not significantly altered by cannabidiol, further suggesting that the compound does not bind with 5-HT binding site. These findings indicate that cannabidiol acts as an allosteric modulator of 5-HT~3~ receptor. Allosteric modulation by cannabidiol has also been reported for several structurally different ion channels \[[@B117-molecules-23-03186]\]. Cannabidiol caused a noncompetitive inhibition of the α7-nicotinic receptors \[[@B91-molecules-23-03186]\] in a manner similar to its action on the 5-HT~3A~ receptors, while it activated glycine receptors and TRPA1 channels \[[@B85-molecules-23-03186],[@B86-molecules-23-03186]\].

4.7. Other Compounds {#sec4dot7-molecules-23-03186}
--------------------

There are other natural compounds derived from plants which also target 5-HT~3~ receptors such as the alkaloids cocaine and morphine (for review \[[@B60-molecules-23-03186]\], both of which are potent competitive inhibitors of 5-HT~3~ receptors (for review, \[[@B12-molecules-23-03186]\]). Interestingly, quinine, the antimalarial drug, is a competitive inhibitor of 5-HT~3A~ receptors whereas it non-competitively inhibits 5-HT~3AB~ receptors with a tenfold less potency \[[@B13-molecules-23-03186]\]. Local anesthetics such as lidocaine and bupivacaine, are also competitive and allosteric antagonists at the 5-HT~3A~ receptor \[[@B122-molecules-23-03186]\].

In the current article, we have reviewed the effects of natural negative allosteric compounds on 5-HT~3~ receptors according to different preparations and a wide variety of techniques, ranging from two-electrode voltage clamp to binding assays. Unlike 5-HT~3~ receptor selective antiemetic drugs which bind at the 5-HT binding site, all the compounds reviewed in this article inhibit the 5-HT~3~ receptor by binding to a modulatory binding site distinct from the 5-HT recognition site. These compounds did not compete with or displace the 5-HT~3~ antagonist, as evident in electrophysiological and ligand binding studies. The therapeutic potential of allosteric ligands stems from their ability to modulate receptor function while maintaining the native pattern of the receptor activation largely intact \[[@B20-molecules-23-03186],[@B21-molecules-23-03186]\]. By decreasing the efficacy of endogenous 5-HT~3~ receptor agonist, negative allosteric modulators of 5-HT~3~ receptors can act as fine-tuning tools that may not affect physiological conditions, but may be very active in pathophysiological states such as CINV, without causing complete receptor inhibition \[[@B12-molecules-23-03186]\]. This would lead to better safety profile compared to competitive antagonists. Since allosteric sites exhibit greater structural diversity than orthosteric sites \[[@B18-molecules-23-03186]\], they are more likely to allow selective targeting by natural modulators.

In conclusion, the identification of allosteric binding sites for natural plant extracts and compounds is expected to possess a promising outcome in developing novel anti-emetics lacking the typical side effects caused by setrons \[[@B106-molecules-23-03186]\]. Considering the reported effects of allosteric modulatory compounds, the development of novel antiemetic drugs based on naturally produced compounds may be possible.
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molecules-23-03186-t001_Table 1

###### 

Summary of natural negative allosteric inhibitors of 5HT~3~ receptor.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Compound                        Concentration              Preparation                                                References
  ------------------------------- -------------------------- ---------------------------------------------------------- -----------------------------------------------------------------------------------
  Menthol                         \>100 µM                   \[^14^C\] guanidinium influx into N1E-115 cells.\          \[[@B44-molecules-23-03186]\]
                                                             Isotonic contractions of the ileum isolated rat.\          
                                                             Equilibrium competition binding studies.                   

  IC~50~ = 163 µM                 *Xenopus laevis* oocytes   \[[@B43-molecules-23-03186]\]                              

  IC~50~ = 4.75 µM\               HEK293 cells\              \[[@B15-molecules-23-03186]\]                              
  IC~50~ = 489 µM                 *Xenopus laevis* oocytes                                                              

  \[[@B45-molecules-23-03186]\]                                                                                         

  Boldine                         IC~50~ = 5.94 µM           HEK293 cells                                               \[[@B15-molecules-23-03186]\]

  Citronellol                     IC~50~ = 64.3 µM           *Xenopus laevis* oocytes                                   \[[@B45-molecules-23-03186]\]

  Geraniol                        IC~50~ = 188 µM            *Xenopus laevis* oocytes                                   \[[@B45-molecules-23-03186]\]

  Citral                          IC~50~ = 120 µM            *Xenopus laevis* oocytes and HEK293 cells                  \[[@B55-molecules-23-03186]\]

  Eucalyptol                      IC~50~ = 258 µM            *Xenopus laevis* oocytes and HEK293 cells                  \[[@B55-molecules-23-03186]\]

  Linalool                        IC~50~ = 141 µM            *Xenopus laevis* oocytes and HEK293 cells                  \[[@B55-molecules-23-03186]\]

  6-shogaol                       100 µM\                    \[^14^C\] guanidinium influx into N1E-115 cells.\          \[[@B56-molecules-23-03186],[@B57-molecules-23-03186]\]
                                  IC~50~ = 3.2--10 µM        Equilibrium competition binding studies.\                  
                                                             Isotonic contractions of the isolated guinea-pig ileum.\   
                                                             Visceral afferent neurons and HEK293 cells.                

  8-gingerol                      1--3 µM\                   \[^14^C\] guanidinium influx into N1E-115 cells.\          \[[@B56-molecules-23-03186]\]
                                  100 µM                     Equilibrium competition binding studies.\                  
                                                             Isotonic contractions of the isolated guinea-pig ileum.    

  6-gingerol                      88 µM\                     \[^14^C\] guanidinium influx into N1E-115 cells.\          \[[@B56-molecules-23-03186],[@B57-molecules-23-03186],[@B58-molecules-23-03186]\]
                                  100 µM\                    Equilibrium competition binding studies.\                  
                                  IC~50~ = 9--30 µM          Isotonic contractions of the isolated guinea-pig ileum.\   
                                                             Visceral afferent neurons and HEK293 cells                 

  10-gingerol                     IC~50~ = 9--15 µM          \[^14^C\] guanidinium influx into N1E-115 cells.\          \[[@B56-molecules-23-03186]\]
                                                             Equilibrium competition binding studies.\                  
                                                             Isotonic contractions of the isolated guinea-pig ileum.    

  Zingerone                       IC~50~ = 1.19 mM           Visceral afferent neurons                                  \[[@B58-molecules-23-03186]\]

  Capsaicin                       IC~50~ = 98.1 µM           *Xenopus laevis* oocytes                                   \[[@B45-molecules-23-03186]\]

  Eugenol                         IC~50~ = 1159 µM           *Xenopus laevis* oocytes                                   \[[@B45-molecules-23-03186]\]

  Vanillin                        IC~50~ = 4744 µM           *Xenopus laevis* oocytes                                   \[[@B45-molecules-23-03186]\]

  Thujone                         \-                         HEK293 cells                                               \[[@B59-molecules-23-03186]\]

  Cannabidiol                     IC~50~ = 0.6 µM            *Xenopus laevis* oocytes                                   \[[@B60-molecules-23-03186]\]

  Quinine                         IC~50~ = 1.06 µM           *Xenopus laevis* oocytes                                   \[[@B13-molecules-23-03186]\]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

molecules-23-03186-t002_Table 2

###### 

Summary of the effects of natural negative allosteric inhibitors of 5HT~3~ on other target proteins.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Compound                   Target protein           Effect                                                                               References
  -------------------------- ------------------------ ------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------
  Menthol                    GABA~A~                  Potentiation                                                                         \[[@B52-molecules-23-03186],[@B53-molecules-23-03186],[@B54-molecules-23-03186]\]

  Glycine                    Potentiation             \[[@B51-molecules-23-03186]\]                                                        

  Nicotinic receptors        Reduction\               \[[@B47-molecules-23-03186],[@B61-molecules-23-03186],[@B62-molecules-23-03186]\]\   
                             Up-regulation            \[[@B63-molecules-23-03186]\]                                                        

  TRP channels               Potentiation             \[[@B49-molecules-23-03186],[@B50-molecules-23-03186]\]                              

  Na^+^ channels             Blocking                 \[[@B64-molecules-23-03186]\]                                                        

  Ca^2+^ channels            Inhibition               \[[@B65-molecules-23-03186],[@B66-molecules-23-03186],[@B67-molecules-23-03186]\]    

  K^+^ channels              Activation               \[[@B68-molecules-23-03186]\]                                                        

  TRP channels               Activation\              \[[@B49-molecules-23-03186],[@B50-molecules-23-03186],[@B69-molecules-23-03186]\]\   
                             Inhibition               \[[@B70-molecules-23-03186]\]                                                        

  Boldine                    TRP channels             Inhibition                                                                           \[[@B71-molecules-23-03186]\]

  Citral                     TRP channels             Activation                                                                           \[[@B72-molecules-23-03186]\]

  Eucalyptol                 Na^+^ channels           Inhibition                                                                           \[[@B73-molecules-23-03186]\]

  TRP channels               Activation               \[[@B74-molecules-23-03186],[@B75-molecules-23-03186],[@B76-molecules-23-03186]\]    

  Linalool                   Na^+^ channels           Inhibition                                                                           \[[@B77-molecules-23-03186]\]

  Nicotinic receptors        Reduction                \[[@B78-molecules-23-03186]\]                                                        

  TRP channels               Activation               \[[@B74-molecules-23-03186],[@B79-molecules-23-03186]\]                              

  Gingerol                   L-type Ca^2+^ channels   Inhibition                                                                           \[[@B80-molecules-23-03186]\]

  6-gingerol                 Na^+^ channels           Blockage                                                                             \[[@B81-molecules-23-03186]\]

  K^+^ channels              Inhibition               \[[@B82-molecules-23-03186]\]                                                        

  6-shogaol                  Na^+^ channels           Blockage                                                                             \[[@B81-molecules-23-03186]\]

  Capsaicin                  K^+^ channels            Inhibition                                                                           \[[@B82-molecules-23-03186]\]

  Eugenol                    T-type Ca^2+^ channel    Inhibition                                                                           \[[@B83-molecules-23-03186],[@B84-molecules-23-03186]\]

  GABA~A~ receptors          Activation               \[[@B85-molecules-23-03186],[@B86-molecules-23-03186]\]                              

  K^+^ channels              Inhibition               \[[@B87-molecules-23-03186],[@B88-molecules-23-03186]\]                              

  Cannabidiol                TRP channels             Activation                                                                           \[[@B74-molecules-23-03186],[@B89-molecules-23-03186],[@B90-molecules-23-03186]\]

  α~7~-nicotinic receptors   Inhibition               \[[@B91-molecules-23-03186]\]                                                        

  Glycine receptors          Activation               \[[@B92-molecules-23-03186]\]                                                        

  Thujone                    TRP channels             Activation                                                                           \[[@B93-molecules-23-03186]\]

  α~7~-nicotinic receptors   Inhibition               \[[@B94-molecules-23-03186]\]                                                        

  GABA~A~ receptors          Inhibition               \[[@B95-molecules-23-03186]\]                                                        
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
